Dianthus Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Dianthus Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Dianthus Therapeutics: 4 sponsored US clinical trials, 3 recruiting.
Dianthus Therapeutics sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Inflammatory Demyelinating Polyneuropathy, with 1 trials.
Upper-quartile sponsor footprint
Dianthus Therapeutics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
NCT06537999
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
What is open in the Dianthus Therapeutics pipeline
3 recruiting of 4 indexed (75% open).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Chronic Inflammatory Demyelinating Polyneuropathy (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dianthus Therapeutics: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Dianthus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
Related
What to do with this Dianthus Therapeutics page
4 registered trials is a research-attention snapshot, not an endorsement of Dianthus Therapeutics or any single study.
- 3 of Dianthus Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Inflammatory Demyelinating Polyneuropathy is the condition Dianthus Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Inflammatory Demyelinating Polyneuropathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dianthus Therapeutics pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.